Theralase Technologies Inc. V.TLT

#ASCO22 Annual Meeting - June 3-7, 2022

[ScienceFirst]

It will be interesting to see what real giant leap innovations come out of ASCO in terms of destruction of solid tumors, no matter the indication. 

I bet that there won't be any, as we would have already heard about them by now, which would once again demonstrate the giant leap that our PDT/PDC treatment is about to deliver if our clinical data keeps delivering similar ratios in the optimized group.

[ScienceFirst]

It will be interesting to see at what efficacy level can Keytruda destroy solid tumors in early-stage cancers.  Remember that we destroy late-stage cancers (as our NMIBC population is left with no more options, other than removing their bladder). So if Keytruda, the biggest blockbuster in the current history of medecine is not able to beat, in early-stage cancers, our efficacy in late-stage

[CancerSlayer]

  In addition to batting cleanup for Keytruda, our drug/ACT has the potential of permanently replacing some forms of chemo that are currently used in the treatment of various solid tumor types imo.  In so doing, our ACT platform could potentially be used as a first-line option for not only late stage solid tumors, but also earlier stage...and if clinical validation continues, I see

[ScienceFirst]

CancerSlayer ... You're right.  The pharma that will decide to jv with us will also find numerous additional indications/stages to TLD-1433, a bit like Merck did it with Keytruda where they integrated it into 400 clinical trials.

[LaserStock29]

So will Roger mention this at the agm or will it be another 2014 Cambridge spoof.. with Amanda Lang.. 'If it works in people' Well Baby.. it works in people...   without any doubt.. and double dose safety.. and efficacy..  Time to get that JV money..  Reading about indications past this is all irrellevant as those concerns as a shareholder are  moot. Endocyte

[ScienceFirst]

Amanda Lang is past history and TLT will first focus on its buyers; oncologists, to generate sales.   Rules also forbid to time news with AGMs.

[LaserStock29]

Did endocyte have to sell any of it's small molecule before its valuation Why are u talking about sales. Will the price not hit $2 until we start selling? Really?

[FGPstock]

Unless i am mistaken, TLT is not going to b at the ASCO22. I am just hoping they have "got the goods" as I heard that a few years ago and would like to see me than .30. Does anyone know if the TLT AGM has been announced and whether it is live or virtual?

[skier59]

My god, has it been over 8 years I've been invested in this stock now? My first purchase of 10,000 shares @ 34 cents still in the red, along with the large group of friends I brought into this stock. Again I ended up buying more to soon not long ago at 40 just before the last report and subsquent crash of the SP. Hopefully one day we will all be rewarded before we die. It appears to be getting

[ScienceFirst]

Remember that TLT has demonstrated in preclinical that TLD-1433 was efficient in other indications.

[ScienceFirst]

Remember that, in August 2017?   Gilead Sciences to Acquire Kite Pharma for 11.9B$US   Provides Broad Pipeline in Hematologic Malignances and Solid Tumors and Robust Platform for Continued Innovation     Now lets see at ASCO 2022, if CAR-T cells are finally delivering real innovation when it comes to efficacy results

[ScienceFirst]

Another big pharma that we could compare against their innovative oncology pipeline, to see where we stand and what they mean about "innovation": SANOFI Media Update: New data from fast-growing innovative Oncology pipeline and portfolio to be presented at 2022 ASCO Annual Meeting Safety and efficacy data for SAR439459, a transforming growth factor beta (TGF-β) inhibitor*

[ScienceFirst]

So funny. In their 2018 animal models (mice), they only obtained tumor regressions in mice.  Not even tumor destructions!  And they have to discriminate among patients (anti-PD-1), so their pool of patients is much narrower (3-4x, or about only 25% of the elegible patients) than would be our PDT/PDC technology. July 2018 Cancer Research 78(13 Supplement):2790-2790

[Sunvalley]

Good Lord! Apparently I have also been here for 8 years .I had thought it was about 6 years but apparently not. My first buy was in the 30,s and have been picking up more here and there ever since that time.at various prices but have been pounding the dips at every opportunity. Have amassed a goodly position and am in the green now but now looking for a big payday , being the greedy person that I